Top

Published in:

01-06-2008 | Original Article

A prospective analysis of testicular androgenic function in recipients of a renal allograft

Authors: Rajiv Yadav, S. N. Mehta, A. Kumar, S. Guleria, V. Seenu, S. C. Tiwari

Published in: International Urology and Nephrology | Issue 2/2008

Abstract

Eighteen adult males with end stage renal disease (ESRD) were studied to determine the serum levels of gonadotropins (LH and FSH), prolactin (PRL) and testosterone. All of the patients were studied longitudinally while undergoing maintenance hemodialysis (HD) and six months after renal transplantation. Prior to transplantation, significantly high levels of gonadotropins and PRL were observed. During HD the serum testosterone levels tended to be subnormal in most of the uremic patients and low normal in some of the subjects. Renal transplantation led to a significant improvement (P < 0.05) in serum testosterone. Elevated gonadotropin and PRL levels observed in patients on HD returned to the normal range in most of the patients after successful renal transplantation.

Stewart Bentely M, Gans D, Horton R (1974) Regulation of gonadal function in uremia. Metabolism 23:1065–1072CrossRef

Lim VS, Fang VS (1975) Gonadal dysfunction in uremic men. A study of the hypothalamo–pituitary–testicular axis before and after renal transplantation. Am J Med 58(5):655–662

Gomez F, de la Cueva R, Wauters JP (1980) Endocrine abnormalities in patients undergoing long-term hemodialyses. The role of prolactin. Am J Med 68:522–530PubMedCrossRef

Guevara A, Vidt D, Hallberg MC, Zorn EM, Pohlman C, Wieland RG (1969) Serum gonadotropin and testosterone levels in uremic males undergoing intermittent dialysis. Metabolism 18:1062–1066PubMedCrossRef

Handelsman DJ (1985) Hypothalamic pituitary gonadal dysfunction in renal failure, dialysis and renal transplantation. Endocrinol Rev 6:151–162

Finkelstein FO, Finkelstein SH, Steele TE (1976) Assessment of marital relationship of hemodialysis patients. Am J Med Sci 21:271

Holdsworth SR, de Kretser DM, Atkins RC (1978) A comparison of hemodialysis and transplantation in reversing the uremic disturbance of male reproductive function. Clin Nephrol 10(4):146–150PubMed

Cowden EA, Ratcliffe WA, Ratcliffe JG, Bobbie JW, Kennedy AC (1979) Hyperprolactinaemia in renal disease. Clin Endocrinol (Oxford) 104:419

Lim VS, Kathpalia SC, Frohman LA (1979) Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation. J Clin Endocrinol Metab 48:101PubMed

10.

Peces R, Horcajada C, Lopez-Novoa JM, Frutos MA, Casado S, Hernando L (1981) Hyperprolactinemia in chronic renal failure: impaired responsiveness to stimulation and suppression. Normalization after transplantation. Nephron 28(1):11–16PubMed

11.

Chen JC, Vidt DG, Zorn RM, Hallberg MC, Wieland RG (1970) Pituitary—Leydig dell function in uraemic males. J Clin Endocr Metab 3:14

12.

Holdsworth S, Atkins RC, de Kretser DM (1977) The pituitary testicular axis in men with chromic renal failure. N Engl J Med 296:1245–1249PubMed

13.

Foulks CJ, Cushner HM (1986) Sexual dysfunction in the male dialysis patient: pathogenesis, evaluation, and therapy. Am J Kidney Dis 8(4):211–222PubMed

14.

Lim VS, Auletta F, Kathpalia S (1978) Gonadal dysfunction in chronic renal failure. An endocrinologic review. Dial Transplant 7:896–907

15.

Talbot JA, Rodger RS, Robertson WR (1990) Pulsatile bioactive luteinizing hormone secretion in men with chronic renal failure and following renal transplantation. Nephron 56(1):66–72PubMed

16.

Ishikawa A, Ushiyama T, Suzuki K, Fujita K (1996) Serum testosterone levels after renal transplantation. Transplant Proc 28(3):1952–1953PubMed

17.

Ishii T, Nagano T, Hara Y et al (1996) Clinical study of male sexual activity on chronic hemodialysis after renal transplantation. Transplant Proc 28(3):1646–1648PubMed

18.

Briefel GR, Tsitouras PD, Kowatch MA (1982) Decreased in vitro testosterone production by isolated Leydig cells from uremic rats. Endocrinology 110:976–981PubMed

19.

Rodger RS, Morrison L, Dewar JH, Wilkinson R, Ward MK, Kerr DN (1985) Loss of pulsatile luteinising hormone secretion in men with chronic renal failure. Br Med J (Clin Res Ed) 291(6509):1598–1600

20.

Kreusser W, Mader H, Haag WD, Ritz E (1982) Diminished response of ovarian cAMP to LH in experimental uremia. Kidney Int 22:272–279PubMedCrossRef

21.

Dunkel L, Raivio T, Laine J, Holmberg C (1997) Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney Int 51:777–784PubMedCrossRef

22.

De Kritser DM, Atkins RC, Paulsen CA (1973) Role of the Kidney in metabolism of luteinizing hormone. J Endocr 58:425

23.

Fung MC, Wah GC, Odel WD (1989) Effect of prolactin on luteinizing hormone-stimulating in isolated perfused rat testis. J Androl 10:37

24.

Carter JN, Tyson JE, Tolis G (1977) Prolactin-secreting tumors and hypogonadism in 22 men. N Engl J Med 296:1245–1249

25.

Molitch ME, Hou SH (1983) Neuroendocrine alterations in systemic disease. Clin Endocrinol Metab 12:825–851PubMedCrossRef

26.

Lim VS, Fang VS (1976) Restoration of plasma testosterone levels in uremic men with clomiphene citrate. J Clin Endocrinol Metab 43:1370–1377PubMedCrossRef

27.

Ramirez G, O’Neill WM, Bloomer HA, Jubiz W (1977) Abnormalities in the regulation of prolactin in patients with chronic renal failure. J Clin Endocrinol Metab 45:658PubMed

28.

Sherins RJ, Patterson AP, Brightwell D et al (1982) Alteration in the plasma testosterone: estradiol ratio: an alternative to the inhibin hypothesis. Ann NY Acad Sci 383:295–306PubMedCrossRef

Title: A prospective analysis of testicular androgenic function in recipients of a renal allograft
Authors: Rajiv Yadav
S. N. Mehta
A. Kumar
S. Guleria
V. Seenu
S. C. Tiwari
Publication date: 01-06-2008
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 2/2008
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-007-9277-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection

Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function

The relationship between arteriovenous fistula blood flow rate and pulmonary artery pressure in hemodialysis patients

Brucella glomerulonephritis resulting in end-stage renal disease: a case report and a brief review of the literature

Relationship between aortic valve sclerosis and left ventricular hypertrophy in chronic haemodialysis patients

Latzko repair for vesicovaginal fistula revisited in the era of minimal-access surgery

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials